Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biocon Of India Acquires All Of Cuban Joint Venture

This article was originally published in PharmAsia News

Executive Summary

India's Biocon Biopharmaceuticals has completed its acquisition of CIMAB of Cuba, a company that has been its partner

You may also be interested in...



Horizon Sees Blockbuster Future For Tepezza After US Approval

Once a pariah because of its price-gouging, the new approval represents a change of tack from Horizon.

Medicinal Products Expert And Established Devices Leader Head Commission’s Medtech Unit

Erik Hansson remains deputy head of devices in a move to the European Commission’s DG Sante from DG Grow. He now answers to a newly appointed devices head who shares a common educational background but whose recent pharmaceutical role may unsettle the devices industry.

QUOTED. 22 January 2020. Steve Niedelman.

Steve Niedelman of the law firm King & Spalding gave manufacturers a few words of advice when prepping their so-called front rooms, where US FDA investigators do the majority of their work during facility inspections. See what he said here.

UsernamePublicRestriction

Register

SC074713

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel